Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 2/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.46 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.45 |
| ▸ | DAO | P14920 | 2/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9783055 | 0.83 | HPGDS (0.45) | HPGDSTAAR1GAAAOC3CAPN1 | |
| SCHEMBL9783052 | 0.83 | HPGDS (0.42) | HPGDSTAAR1GAAAOC3CAPN1 | |
| SCHEMBL9783079 | 0.82 | HPGDS (0.41) | HPGDSTAAR1GAAAOC3CAPN1 | |
| SCHEMBL16016402 | 0.81 | MAPT (0.42) | HPGDSTAAR1GAA | |
| SCHEMBL1507946 | 0.77 | HRH3 (0.47) | HRH3 | |
| SCHEMBL11552467 | 0.76 | HPGDS (0.50) | HPGDSTAAR1GAAAOC3CAPN1 | |
| SCHEMBL7688678 | 0.76 | HPGDS (0.50) | HPGDSTAAR1GAAAOC3CAPN1 | |
| SCHEMBL4439049 | 0.76 | HPGDS (0.50) | HPGDSTAAR1GAAAOC3CAPN1 | |
| Hydrochloric Acid SCHEMBL11382369 | 0.74 | HIF1A (0.38) | HPGDSTAAR1PDE10AKMT2A | |
| SCHEMBL8957090 | 0.74 | HRH1 (0.62) | HPGDSTAAR1GAAAOC3CAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040053970-A1 | Prenylation inhibitors and methods of their synthesis and use | PPD DISCOVERY, INC. | 2004-03-18 | — | — | US | claimed |
| US-6664277-B1 | O-dichlorophenyl-pyridinyl-pyrazolyl-amido derivatives; geranylgeranyl-protein transferase inhibitors | PPD DISCOVERY, INC. | 2003-12-16 | — | — | US | claimed |
| US-7501444-B2 | Prenylation inhibitors and methods of their synthesis and use | PPD DISCOVERY, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-20070010561-A1 | PRENYLATION INHIBITORS AND METHODS OF THEIR SYNTHESIS AND USE | PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC | 2007-01-11 | — | — | US | disclosed |
| US-7112596-B2 | Prenylation inhibitors and methods of their synthesis and use | PPD DISCOVERY, INC. (US) | 2006-09-26 | — | — | US | disclosed |
| US-20060025454-A1 | Prenylation inhibitors and methods of their synthesis and use | PPD DISCOVERY, INC. (US) | 2006-02-02 | — | — | US | disclosed |
| US-6960603-B2 | Prenylation inhibitors and methods of their synthesis and use | PPD DISCOVERY, INC. (US) | 2005-11-01 | — | — | US | disclosed |
| US-20040053970-A1 | Prenylation inhibitors and methods of their synthesis and use | PPD DISCOVERY, INC. | 2004-03-18 | — | — | US | disclosed |
| US-6664277-B1 | O-dichlorophenyl-pyridinyl-pyrazolyl-amido derivatives; geranylgeranyl-protein transferase inhibitors | PPD DISCOVERY, INC. | 2003-12-16 | — | — | US | disclosed |
| US-6649638-B1 | 5-Pyridin-3-yl-1H-pyrazole-3-carboxylic amide derivatives; cancer, restenosis, psoriasis, endometriosis, atherosclerosis, viral or yeast infection, and corneal neovascularization treatment | PPD DISCOVERY, INC. | 2003-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025454-A1 | Prenylation inhibitors and methods of their synthesis and use | FNTA, RCE1, GGPS1 | HPGDS 240/4885TAAR1 4864/4885GAA 2152/4885 |
| US-20040053970-A1 | Prenylation inhibitors and methods of their synthesis and use | FNTA, RCE1, GGPS1 | HPGDS 240/4885TAAR1 4864/4885GAA 2152/4885 |
| US-20070010561-A1 | PRENYLATION INHIBITORS AND METHODS OF THEIR SYNTHESIS AND USE | FNTA, RCE1, GGPS1 | HPGDS 240/4885TAAR1 4864/4885GAA 2152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.